Atara Biotherapeutics, Inc. (ATRA) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everyone. Thank you for standing by and welcome to the Altara Biotherapeutics first quarter 2022 financial results conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone to require operator assistance during the conference, please press star zero on your telephone keypad. Please be advised that today's call is being recorded. I'd now like to hand the call over to Eric Halligren, Vice President of Investor Relations and Finance at Atara Biotherapeutics. Please proceed, sir. Thank you, Operator. Good afternoon, everyone, and welcome to Atara's first quarter 2022 results conference call. Earlier today, we issued a press release announcing our first quarter financial results and operational progress. This press release and an updated slide deck are available in the Investors and Media section at atarabio.com. On today's call, members from the ATARA executive team will provide an update on our financial results and operational progress, and also review our upcoming key milestones and objectives. Joining me on today's call are Dr. Pascal Tuchon, President and Chief Executive Officer, Dr. Jacob Dupont, Executive Vice President and Global Head of Research and Development, Upal Kopikar, Chief Financial Officer, Dr. A.J. Joshi, Chief Medical Officer, and Dr. Kristen Urema, Chief Commercial Officer. We will begin with prepared comments from Pascal and Jacob, then open up the call for your questions. We would like to remind listeners that during the call, the company's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associate...